Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands

Trial Profile

Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary) ; Alteplase (Primary) ; Urokinase (Primary)
  • Indications Embolism and thrombosis; Haemorrhage; Stroke
  • Focus Therapeutic Use
  • Acronyms MR CLEAN
  • Most Recent Events

    • 11 Jan 2022 Results of MR CLEAN Registry Substudy assessing clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment published in the Neurology
    • 14 Oct 2021 Results assessing whether endovascular therapy plus usual care is cost-effective in comparison to usual care alone in acute ischemic stroke patients, published in the Stroke.
    • 20 Sep 2021 Results (n=1161) evaluating the associations of systolic BP in the first 6 hours following EVT with functional outcome and the occurrence of symptomatic intracranial hemorrhage, published in the Stroke
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top